|
Originally published In Press as doi:10.1074/jbc.M202560200 on September 5, 2002
J. Biol. Chem., Vol. 277, Issue 45, 43281-43287, November 8, 2002
The Translational Regulation of Lipoprotein Lipase
by Epinephrine Involves an RNA Binding Complex Including the Catalytic
Subunit of Protein Kinase A*
Gouri
Ranganathan,
Dan
Phan,
Irina D.
Pokrovskaya,
Joan E.
McEwen,
Chunling
Li, and
Philip A.
Kern
From the Central Arkansas Veterans HealthCare System, and
Department of Medicine, Division of Endocrinology, and the
Department of Geriatrics, University of Arkansas for Medical Sciences,
Little Rock, Arkansas 72205
Received for publication, March 15, 2002, and in revised form, September 4, 2002
 |
ABSTRACT |
The balance of lipid flux in adipocytes is
controlled by the opposing actions of lipolysis and lipogenesis, which
are controlled primarily by hormone-sensitive lipase and
lipoprotein lipase (LPL), respectively. Catecholamines stimulate
adipocyte lipolysis through reversible phosphorylation of
hormone-sensitive lipase, and simultaneously inhibit LPL activity.
However, LPL regulation is complex and previous studies have described
translational regulation of LPL in response to catecholamines because
of an RNA-binding protein that interacts with the 3'-untranslated
region of LPL mRNA. In this study, we identified several protein
components of an LPL RNA binding complex. Using an LPL RNA affinity
column, we identified two of the RNA-binding proteins as the catalytic
(C) subunit of cAMP-dependent protein kinase (PKA), and A
kinase anchoring protein (AKAP) 121/149, one of the PKA anchoring
proteins, which has known RNA binding activity. To determine whether
the C subunit was involved in LPL translation inhibition, the C subunit
was depleted from the cytoplasmic extract of epinephrine-stimulated
adipocytes by immunoprecipitation. This resulted in the loss of LPL
translation inhibition activity of the extract, along with decreased
RNA binding activity in a gel shift assay. To demonstrate the
importance of the AKAPs, inhibition of PKA-AKAP binding with a peptide
competitor (HT31) prevented epinephrine-mediated inhibition of LPL
translation. C subunit kinase activity was necessary for LPL RNA
binding and translation inhibition, suggesting that the phosphorylation
of AKAP121/149 or other proteins was an important part of RNA binding
complex formation. The hormonal activation of PKA results in the
reversible phosphorylation of hormone-sensitive lipase, which is the
primary mediator of adipocyte lipolysis. These studies demonstrate a
dual role for PKA to simultaneously inhibit LPL-mediated
lipogenesis through inhibition of LPL translation.
 |
INTRODUCTION |
Lipoprotein lipase
(LPL)1 is a central enzyme in
lipid metabolism and hydrolyzes the core of triglyceride-rich plasma
lipoproteins into nonesterified fatty acids and monoacylglycerol
(1). In adipose tissue and muscle, LPL is localized to the capillary
endothelium, and contributes to the rapid removal of triglyceride-rich
lipoproteins and their remnants.
Catecholamines are of considerable physiologic importance in the
mobilization of adipose tissue lipid in response to fasting and
exercise. Hormones that cause elevated cAMP ( -adrenergic agonists,
ACTH, and glucagon) result in the activation of
cAMP-dependent protein kinase A (PKA), which then activates
hormone-sensitive lipase (HSL) (2, 3). HSL is the primary mediator of
adipocyte lipolysis (4), and the release of nonesterified fatty acids from adipocytes play a central role in obesity and insulin resistance (5, 6). On the other hand, LPL hydrolyzes lipoproteins at the capillary
endothelium generating nonesterified fatty acids for triglyceride
storage. LPL and HSL serve opposing functions in adipose tissue, and
they respond in an opposite fashion in response to hormonal regulation.
In adipocytes, insulin and the fed state result in an increase in LPL
activity along with a decrease in HSL activity, whereas hormones that
are elevated during the fasting state, such as epinephrine and
glucagon, inhibit LPL activity and stimulate HSL-mediated lipolysis
(7-9).
Although the decrease in LPL activity by catecholamines has been
described previously (7), the cellular mechanisms controlling LPL
inhibition are complex. In rat adipocytes, we found that the LPL
synthetic rate was inhibited more than 5-fold within 30 min of addition
of epinephrine to the medium, with no change in LPL mRNA levels
(10). Studies of 3T3 adipocytes demonstrated that the inhibition of LPL
translation by epinephrine involved an RNA-binding protein that
interacted with the proximal 3'-untranslated region (UTR) of the LPL
mRNA (11). Subsequent studies found the first 24 nucleotides of the
LPL 3'-UTR essential for translational regulation, and a 30-kDa
RNA-binding protein was identified by cross-linking as an important
component of LPL translational regulation (12).
This study was intended to identify the components involved in the
translational regulation of LPL following cAMP elevation. As described
below, we have identified the catalytic (C) subunit of PKA as the
important 30-kDa protein involved in LPL translational regulation.
However, the C subunit of PKA is likely part of an RNA binding complex,
which also involves A kinase anchoring protein (AKAP) 121/149, which is
involved in binding the PKA holoenzyme, and which contains a known RNA
binding domain (13).
 |
MATERIALS AND METHODS |
Purification of the RNA-binding Protein--
Approximately 100 T-75 flasks of 3T3-F442A adipocytes, representing ~109
cells, were induced to differentiate with insulin, and after 8 days of
differentiation they were treated with epinephrine (10 5
M). LPL translation was inhibited in these cells, and a
cytoplasmic extract was prepared as described previously (11). In
brief, adipocytes were scraped from the plate and the cell pellet was resuspended in 10× the pellet volume of lysis buffer (50 mM Tris-HCl, pH 7.4, 250 mM sucrose, 35 mM KCl, 10 mM MgCl2, 0.5 mM EDTA, 7 mM -mercaptoethanol), and
homogenized with 10 strokes of a glass homogenizer. Homogenates were
centrifuged at 10,000 × g for 15 min at 4 °C. The
postnuclear extract was used to prepare a high speed supernatant
fraction (S-100) by centrifugation at 100,000 × g for
2 h at 4 °C. Solid ammonium sulfate was added to the cytosolic fraction to 60% saturation and precipitated for 1/2 h on ice.
Precipitated proteins were collected by centrifugation at 6,000 × g for 10 min at 0 °C, redissolved and dialyzed against
Buffer A (20 mM Tris-HCl, pH 7.4, 20 mM KCl, 7 mM -mercaptoethanol, 0.1 mM EDTA, and 2 mM phenylmethylsulfonyl fluoride). The sample was then
diluted to 25 ml and passed through a DEAE-cellulose column
equilibrated in 20 mM Tris-HCl, pH 7.4. After washing the
column with the same buffer, proteins were eluted with 5 ml of buffer
containing 400 mM KCl. The DEAE fraction that passed
unbound through the column demonstrated LPL RNA binding properties, as
demonstrated by a gel shift experiment, whereas the 400 mM
KCl eluted fraction had no RNA binding activity. Therefore, the
flow-through was dialyzed against the initial column buffer, and
fractionated on a LPL 3' UTR-oligo(dT)-Sepharose column.
To prepare the RNA binding column, poly(A) RNA transcripts were
generated containing the C-terminal 50 nucleotides of coding sequence,
and the first 100 nucleotides of the LPL 3'-UTR (nucleotides 1512 to
1635). A tracer amount of [32P]UTP was also added during
transcription, to follow the binding and quality of the RNA. The
poly(A) RNA was incubated with presoaked poly(T)-Sepharose beads for 60 min, and packed into a column. The column was washed with low salt
buffer (20 mM Tris-HCl, pH 7.4, 20 mM KCl) to
remove the unbound excess RNA.
For the initial binding reaction, the epinephrine-treated 3T3-F442A
adipocyte extracts were added in low salt (20 mM KCl) buffer containing heparin and yeast tRNA to prevent degradation and
inhibit nonspecific binding. After washing extensively, bound proteins
were eluted with a salt gradient varying from 0.1 to 0.5 M
KCl in 20 mM Hepes, pH 7.5. Fractions were dialyzed against 40 mM KCl buffer, and analyzed by SDS-PAGE with colloidal
blue staining (Novex), as described under "Results."
Peptide Sequencing--
To obtain sequence information, pooled
column fractions from the LPL 3'-UTR column were run on a preparatory
10% polyacrylamide gel. Parallel lanes were stained for
identification, and a discrete band at 30 kDa was cut from a wet gel
and sent to the Harvard Microchemistry facility (Cambridge, MA) for
sequencing. The sequence analysis was performed on tryptic fragments by
microcapillary reverse-phase high performance liquid chromatography
nanoelectrospray tandem mass spectrometry on a Finnigan LCQ quadrupole
ion trap mass spectrometer.
In Vitro Translation--
In vitro translation of RNA
transcripts was performed as described previously (11). RNA transcripts
were made from an LPL cDNA construct (LPL 35 of Wion et
al. (14)). Equal quantities of RNA transcripts (0.1 µg) were
translated in a rabbit reticulocyte lysate system (Promega) in the
presence of [35S]methionine, and the translation products
were analyzed by SDS-PAGE and autoradiography. The intensity of the
images was quantitated with the Eagle SightTM 3.0 image
capture and analysis software (Stratagene 2, La Jolla, CA). We
previously demonstrated that cell extracts from epinephrine-treated cells inhibited LPL translation in vitro (11, 12). The cell extracts (S-100 fractions) from control and epinephrine-treated adipocytes were prepared as described above followed by ammonium sulfate precipitation and dialysis against buffer A. Protein
concentration in the cell extract was determined with a Bio-Rad protein
assay, with bovine serum albumin as a standard. Equal quantities of the cell extract (0.1 µg) were used in the rabbit reticulocyte lysate reaction and the reaction was carried out for 60 min. To assess the
role of PKA C subunit, a specific antibody to the C subunit (polyclonal antibody to the C terminus, Santa Cruz Biotechnology) was
added to the cell extract 30 min prior to addition to the in
vitro translation reaction. As a control, extracts were treated with antibodies to -actin (Calbiochem).
RNA Gel Shift--
To assess the binding of the epinephrine cell
extract to LPL RNA sequences, a [32P]RNA sequence
corresponding to the proximal 3'-UTR of LPL (nucleotides 1512 to 1635)
was synthesized. This 32P-labeled transcript (50,000 cpm)
was incubated for 20 min in buffer A containing 10 µg/ml yeast tRNA,
10 units/ml heparin sulfate, along with 5 µg of cytoplasmic extract
from control or epinephrine-treated 3T3-F442A adipocytes, and the
products were analyzed on a 5% nondenaturing polyacrylamide gel. In
some experiments, PKA C subunit was removed from the cell extract
prior to incubation with the [32P]RNA. To eliminate PKA
C from the extracts, 0.1 µg of anti-C antibody was incubated
with the cell extract followed by 5 µl of 1:1 diluted protein
A-agarose beads. The extract was centrifuged at 1500 × g, and the C -depleted supernatant was then added to the
32P-transcript and gel shift analysis was performed as
described above. The effect of the anti-C antibodies was compared
with irrelevant antibodies ( -actin). In additional experiments, PKA C subunit (0.5 Units, Calbiochem) was added back after
immunoprecipitation of C . To inhibit PKA activity, cells were
pretreated for 15 min with H89 (10 mM, Sigma), which is a
specific inhibitor of the C ATP binding site (15), followed by
epinephrine treatment as described above. The gel shift was then
performed as described above.
Northern, Western, and Ligand Blotting--
RNA was extracted
from adipocytes (16), and equal amounts of total RNA were resolved by
electrophoresis in 2.2 M formaldehyde, 1% agarose
gels. Northern blots were probed using [32P]dCTP-labeled
cDNA probes to AKAP149 and glyceraldehyde-3-phosphate dehydrogenase, which have been reported previously (17, 18). Antibodies
to AKAP149 (Santa Cruz Biotechnology) were directed against the
C-terminal region of the molecule, which is homologous with AKAP121,
but not with other AKAPs (13, 19). Antiphosphoserine antibodies were
obtained from Zymed Laboratories, San Francisco, CA. Western
blotting was performed as described previously (20). Samples containing
15 µg of total protein were fractionated by 10% SDS-PAGE and
transferred onto nitrocellulose membranes. Membranes were treated with
20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.2%
Tween 20, and 5% nonfat dry milk overnight at 4 °C. Secondary
antibodies were antispecies-specific peroxidase-labeled IgG (Sigma).
Ligand blotting with [32P]PKA RII subunit was performed
as described previously (21).
To determine whether the PKA C subunit was associated with AKAP149/121,
co-precipitation experiments were performed as described previously
(22). Epinephrine-treated cells were lysed in phosphate-buffered saline
containing 0.1% SDS, 0.5% sodium deoxycholate, and protease inhibitors and immunoprecipitated with either anti-PKA C antibodies or anti-AKAP149/121 antibodies. These immunoprecipitated products were
analyzed on SDS-PAGE, followed by ligand blotting with the [32P]PKA RII subunit, as described above.
LPL Synthetic Rate--
The LPL synthetic rate was measured in
cultured 3T3-F442A cells as described previously (23). Cells were
incubated in methionine-free medium for 2 h prior to the addition
of 50 µCi of [35S]methionine for 30 min. The cells were
lysed and immunoprecipitated with anti-LPL antibodies (24), followed by
analysis of the samples on a 10% polyacrylamide-SDS gel, followed by
autoradiography. Within each experiment, an aliquot of cell lysate was
precipitated with trichloroacetic acid and counted, and the amount of
lysate taken for immunoprecipitation was adjusted to give equal
trichloroacetic acid counts. To study the effects of AKAP-PKA
disruption (25), 10 µg of myristylated HT31 (Promega) was added to
the cells for 15 min prior to epinephrine treatment.
 |
RESULTS |
When adipocytes were treated with epinephrine, LPL translation was
inhibited (12), and the epinephrine-treated cell extract caused a gel
shift when added to a [32P]RNA fragment corresponding to
LPL mRNA nucleotides 1512 to 1635 (Fig.
1A). To purify the RNA-binding
protein, our methodology was designed to take advantage of the affinity
of the RNA-binding protein for the 3'-UTR of LPL. When the
epinephrine-treated cell extract was applied to a DEAE column, as
described under "Materials and Methods," the RNA binding properties
of the extract were predominantly found in the unbound fraction from
the column. This material was then dialyzed against a low salt buffer
(see "Materials and Methods"), and applied to a poly(U)-Sepharose
column containing the relevant binding region of the 3'-UTR of the LPL
mRNA. After washing the column extensively with the initial column
buffer, increasing salt concentrations were applied, and the gradual
elution of proteins was monitored by SDS-PAGE and colloidal blue
staining.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 1.
Proteins that bind to the 3'-UTR of the LPL
mRNA. A, gel shift assay. As described under
"Materials and Methods," a cell extract was prepared from control
(C), and epinephrine (E)-treated cells and added
to the [32P]RNA corresponding to the proximal LPL 3'-UTR,
followed by analysis by nondenaturing polyacrylamide gel. T,
transcript alone; C, transcript plus control cell extract;
E, transcript plus epinephrine-treated cell extract. This
figure is representative of eight similar experiments. B,
proteins eluted from the LPL 3'-UTR column. As described under
"Materials and Methods," the cell extract was precipitated with
ammonium sulfate, passed through a DEAE-cellulose column, and then
passed through a column containing nucleotides 1512 to 1635 of LPL
mRNA. Fractions were then eluted off with progressively higher salt
concentrations, analyzed by SDS-PAGE, and the gel was stained with
colloidal blue. Lanes 1, 2, 5, and
6, 100 mM KCl; lanes 3 and
7, 250 mM KCl; lanes 4 and
8, 500 mM KCl. This figure is representative of
four experiments.
|
|
Fig. 1 shows the stained gel of the column elution fractions from the
3'-UTR column. With progressive salt elution, we observed the
appearance of a predominant protein that migrated at 30-35 kDa. Other
less prominent bands were also apparent, mostly at higher molecular
weights. A cytoplasmic extract from control cells, which had been
through the same column procedures, demonstrated essentially no
proteins eluting from the RNA binding column except for a faint
30-35-kDa band (Fig. 1, lanes 5-8). In addition, no proteins were eluted when an epinephrine-treated cell extract was
passed through a column containing irrelevant RNA (data not shown).
Because of our previous identification of a cross-linked band at about
30-35 kDa (12), the prominent 35-kDa band was cut from the wet gels,
and subjected to sequence analysis of proteolytic peptides from this
band. The results demonstrated the presence of several proteolytic
fragments belonging to the C subunit of PKA. Peptides to
aldolase and cyclophilin were also identified inconsistently. Because
these are abundant cellular proteins and do not fit a known mechanism
for LPL regulation, further studies were not pursued. There were no
unassigned peptides.
Role of PKA C in Translation Inhibition--
As a result of the
elution of PKA C subunit from the LPL RNA affinity column, we sought
additional evidence that this subunit was involved in the inhibition of
LPL translation. To further characterize this interaction, and to
obtain direct evidence for PKA C binding to the LPL mRNA, we
performed a gel shift assay. A 32P-labeled transcript
corresponding to nucleotides 1512 to 1635 of the LPL mRNA was
incubated with the control and epinephrine-treated cell extracts. As
shown in Fig. 2, the cell extract from
epinephrine-treated cells resulted in a gel shift (lane 2)
when compared with the control extract (lane 1). To confirm
the role of PKA C subunit, we added anti-PKA C antibody to the
epinephrine-treated cell extract, followed by protein A-agarose, to
immunoprecipitate the PKA C subunit. This PKA C -depleted extract
was then added to the [32P]RNA transcript in a gel shift
reaction. As shown in Fig. 2 (lane 3), there was a greatly
reduced intensity of the shifted band, and the addition of less
anti-PKA C antibody resulted in a greater intensity of the
gel-shifted band (lane 4). The addition of irrelevant antibodies did not reduce the intensity of the shifted band (data not shown). To determine whether we could then restore RNA binding, we
added active PKA C (0.5 units) back to the PKA C -depleted cell
extract. Addition of C subunit after the immunoprecipitation restored and augmented the mobility gel shift (Fig. 2, lane
5). However, the addition of the active PKA C protein to the
[32P]RNA, in the absence of cell extract, did not cause a
gel shift (lane 6), suggesting that the PKA C subunit is
part of a binding complex that involves other proteins.

View larger version (76K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of PKA C subunit on LPL RNA
binding. A 123-nucleotide [32P]RNA fragment
corresponding to the proximal 3'-UTR of LPL was incubated in the
presence of either cell extract, followed by the addition of RNase.
Lane 1, the transcript was incubated with control cell
extract. Lane 2, epinephrine-treated cell extract.
Lane 3, epinephrine-treated cell extract from which the C
subunit was immunoprecipitated prior to incubation with the
[32P]RNA by the addition of 0.5 µg of anti-C
antibody followed by the addition of protein A. Lane 4, same
as lane 3, except for the addition of only 0.05 µg of
anti-C antibody. Lane 5, same as lane 3,
except for the addition of 5 units of activated PKA C following the
immunoprecipitation. Lane 6, activated PKA C (5 units)
was added to the [32P]RNA transcript in the absence of
cell extract. This figure is representative of three similar
experiments.
|
|
The above experiments demonstrate the involvement of PKA C in RNA
binding, but do not necessarily imply inhibition of translation. As
described previously, the cell extract from control adipocytes inhibited LPL translation in vitro when compared with the
addition of no extract, and epinephrine-treated cell extract yielded a much greater inhibition of LPL translation (11, 12). To determine whether the PKA C subunit is involved in translation inhibition, antibodies to PKA C were added to the in vitro
translation reaction containing the LPL mRNA and cell extracts. As
shown in Fig. 3, the cytoplasmic extract
from epinephrine-treated cells inhibited LPL translation in
vitro (lane 2). However, when the PKA C subunit was
immunoprecipitated from the epinephrine-treated cell extract, the
inhibition of LPL translation was abolished (lane 4).
Indeed, the in vitro translation of LPL was increased in
both the control and epinephrine-treated cell extracts after depletion
of PKA C , which likely reflected the constitutive presence of the
PKA C subunit. Addition of irrelevant antibody had no effect on the proportional change in LPL translation because of control and epinephrine extracts, although there was a small nonspecific decrease in translation in both lanes 5 and 6 (Fig. 3).
Thus, these data suggested that PKA C subunit was involved in LPL
translation inhibition.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of antibody to PKA C subunit on LPL
translation in vitro. Cytoplasmic extracts
were prepared, as described under "Materials and Methods," and
added to the in vitro translation reaction in the presence
of LPL mRNA (nucleotides 1-2435). Con and
Epi refers to the addition to the in vitro
translation reaction of the cytoplasmic extracts from control or
epinephrine-treated 3T3-F442A adipocytes. Anti-C and
anti-actin refers to the addition of antibody to either PKA
C or actin (irrelevant antibody). A, SDS gels of the
in vitro translation reactions. This figure is
representative of three experiments. B, bar graph
demonstrating the relative density of each reaction.
|
|
Other Components of the RNA Binding Complex--
These data
indicated that the C subunit was not by itself sufficient to cause a
gel shift or inhibit translation, and suggested the presence of other
proteins as part of a complex. PKA regulatory subunit was not detected
by Western blotting of the column eluate from the epinephrine-treated
cell extract (data not shown). Indeed, the R subunit was tightly bound
to the DEAE column, and was not present in either the flow-through or
the high salt wash. However, one class of proteins that is known to
anchor PKA through the regulatory subunit is the AKAPs. To determine
whether AKAPs were involved in the RNA binding complex, we used the
32P-labeled PKA regulatory subunit to perform ligand
blotting of the elute from the LPL RNA affinity column described in
Fig. 1. As shown in Fig. 4B
(lane 1), a ligand blot of the proteins eluted off the
column at 500 mM KCl demonstrated two bands: the expected band at 30 kDa, which represented the C subunit, and a band that migrated with a molecular mass between the markers at 116 and 205 kDa.

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 4.
Identification of AKAP121/149 as an LPL RNA
binding protein. A, from both control and
epinephrine-treated cells, a cell extract was prepared as described for
Fig. 1, and then passed through a column containing nucleotides 1512 to
1635 of LPL mRNA. Fractions were then eluted off the LPL RNA column
with progressively higher salt concentrations, analyzed by SDS-PAGE,
and then blotted with specific antibodies to AKAP121/149. The lanes are
the same as in Fig. 1: lanes 1, 2, 5,
and 6, 100 mM KCl; lanes 3 and
7, 250 mM KCl; lanes 4 and
8, 500 mM KCl. Arrow marks the
migration of the AKAP121/149 band. B, a cell extract was
prepared from epinephrine-treated cells as described above, and eluted
off the LPL 3'-UTR column with 500 mM KCl, dialyzed, and
subjected to SDS-PAGE. Lane 1, this fraction was blotted
with the 32P-labeled PKA RII subunit as a ligand blot.
Lane 2, this fraction was Western blotted with
anti-phosphoserine antibodies. C, Northern blot from
control (C) and epinephrine (E)-treated
adipocytes.
|
|
AKAP121/149 is a member of the AKAP family of PKA-binding proteins that
are notable for a consensus KH domain (26, 27), which is found in many
known RNA-binding proteins (28). To determine whether the slower
migrating band from the ligand blot was AKAP121/149, we performed
Western blotting with specific antibodies to AKAP121/149. As shown in
Fig. 4A, the anti-AKAP121/149 antibodies identified the same
protein that was identified in the ligand blot. In addition, the
anti-AKAP antibodies did not detect any AKAP121/149 in the 3'-UTR
column eluate from the control cell extract fraction, or from the lower
salt eluate from the epinephrine-treated cells. A negative result was
obtained when the blot was probed with antibodies to AKAP150, which has
no C-terminal homology to AKAP121/149, but which has a similar
migration (data not shown). Hence, AKAP121/149 and the PKA C subunit
co-eluted from the 3'-UTR LPL mRNA column. The PKA kinase activity
has numerous targets, and we performed Western blots with
antiphosphoserine antibodies to determine whether any proteins from the
3'-UTR LPL mRNA column were phosphorylated. As shown in Fig.
4B, the same band identified as AKAP121/149 was also
identified by the antiphosphoserine antibodies, suggesting that
AKAP121/149 is phosphorylated. Antiphosphoserine antibodies identified
no other proteins from the 3'-UTR column, and identified no proteins
from the control cell extract column (data not shown). The C subunit
was present, as described above, but was not detected with
antiphosphoserine antibodies, suggesting that it became
dephosphorylated during the purification.
PKA C and AKAP121/149 Are Involved in LPL Translation
Inhibition--
To determine whether AKAP is functionally involved
with the inhibition of LPL translation, we used HT31 to inhibit
cellular AKAP-PKA binding. HT31 is derived from the consensus peptide
motif on AKAPs that bind to the R subunit of PKA (25). LPL was
immunoprecipitated from cells treated with myristylated HT31 with and
without the presence of epinephrine, and labeled with
[35S]methionine. As shown in Fig.
5, epinephrine inhibited LPL synthesis, and this inhibition was disrupted by HT31. Indeed, the translation of
LPL was up-regulated in both control and epinephrine-treated cells,
suggesting that AKAPs are involved in a constitutive inhibition of LPL
even in control cells. Hence, this experiment demonstrated a functional
role of the AKAPs in LPL translation inhibition by epinephrine.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of inhibition of AKAP-PKA binding on
epinephrine-mediated inhibition of LPL translation. As described
under "Materials and Methods," both control and epinephrine-treated
3T3-F442A adipocytes were treated with HT 31 prior to pulse labeling
with [35S]methionine. LPL was immunoprecipitated from the
cells with specific antibody. C, control cells.
E, epinephrine-treated cells. This figure is representative
of two experiments.
|
|
To determine whether PKA C and AKAP149/121 were associated with each
other as a complex, co-precipitation experiments were performed. Cell
lysates from epinephrine-treated adipocytes were immunoprecipitated
with either anti-C antibodies or anti-AKAP149/121 antibodies,
followed by either Western blotting with the other antibody or ligand
blotting with 32P-regulatory subunit. No association
between AKAP121/149 and C subunit was detected using this method (data
not shown). Thus, both PKA C and AKAP149/121 appeared to be binding
to the LPL 3'-UTR, but were not associated with each other.
The kinase activity of the PKA C subunit may be important in mediating
LPL mRNA binding. To determine whether PKA C kinase activity was
important, we treated cells with H89 (10 µM), which is a
specific inhibitor of the C ATP binding site (15). This treatment
would permit cAMP mediated release of the C subunit, but the subunit
would be catalytically inactive. As shown in Fig. 6, a gel-shifted band was present in
epinephrine-treated cells (a weaker gel-shifted band was present in
control cells, which likely represents a small amount of baseline PKA
activation). The addition of H89 to the cells 15 min prior to
epinephrine treatment resulted in a reduced ability to form an RNA
binding complex, as illustrated by the diminished gel shift associated
with the epinephrine-treated cell extract (Fig. 6). Thus, PKA C
kinase activity was necessary for the formation of the gel-shift RNA binding complex.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of H89, an inhibitor of
C kinase activity, on RNA binding complex
formation. 32P-RNA corresponding to the 3'-UTR of LPL
was incubated with control (C) and epinephrine
(E)-treated cell extract from cells that had been treated
with H89 (H89-E, 10 mM), followed by a gel-shift experiment
as described under "Materials and Methods." Arrow
indicates the shifted band from the RNA binding. These data are
representative of three similar experiments.
|
|
To further examine the effects of PKA kinase inhibition, in
vitro translation experiments were performed with the cell
extracts from control, epinephrine-treated, and H89-epinephrine-treated cells. The in vitro translation reactions were allowed to
proceed for increasing time periods from 10 to 35 min. As shown in Fig. 7, all the cell extracts yielded some
inhibition of translation when compared with the addition of no
extract. This is consistent with the constitutive presence of the RNA
binding complex. The epinephrine-treated cell extract yielded the most
inhibition of LPL translation, and extract from cells treated with both
epinephrine and H89 demonstrated in vitro translation that
was similar to that of control cells. Thus, these data suggest that PKA
kinase activity is important to both RNA binding, and translation.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 7.
LPL in vitro translation in
the presence of H89. In vitro translation reactions
using LPL mRNA were performed in the absence and presence of cell
extracts from control (Con), epinephrine (Epi),
and epinephrine-H89 treated cells, as described under "Materials and
Methods." A, in vitro translation reactions
were allowed to proceed for the indicated times. B,
densitometric analysis of the image in A. These data are
representative of two experiments.
|
|
 |
DISCUSSION |
LPL is an important enzyme in adipocyte biology and is highly
regulated in response to numerous physiologic conditions and hormones
(7). The mechanism of LPL regulation is complex, and may occur at the
level of transcription, post-translational processing, or translation
(23, 29-31). Changes in LPL translation have been demonstrated in
response to the addition of epinephrine (10), glucose (32), and thyroid
hormone (10). In addition, adipocyte LPL is translationally repressed
in both humans and rats with diabetes (33-35). In previous studies, we
examined the inhibition of LPL translation by epinephrine, and found
that the important region of the LPL mRNA was in the first 24 nucleotides of the 3'-UTR (11). The identification of this region of
the 3'-UTR was accomplished by in vitro translation with
different RNA constructs, along with RNase protection assays, and
transient transfection experiments (12). Subsequent studies of UV
cross-linking the LPL mRNA binding region to an epinephrine-treated
cell extract identified a 30-kDa protein as a likely candidate for the
regulatory RNA-binding protein (12). The studies described in this
paper were performed to better characterize the protein(s) involved in
binding to the LPL 3'-UTR.
The initial identification of the RNA-binding protein utilized an RNA
affinity column containing 123 nucleotides of the LPL RNA that is
involved in translational regulation. The predominant protein that
eluted from this column was at 30 kDa, and sequencing determined that
this protein was the C subunit of PKA. The presence of PKA C
subunit in the column eluate does not by itself demonstrate a role in
LPL translational regulation. However, further experiments demonstrated
that removal of the C subunit prevented translation inhibition
in vitro, and prevented the gel shift caused by the epinephrine-treated cell extract. Thus, the presence of the C subunit of PKA in the cell extract was not coincidental, but was important to translational regulation. Although removal of C subunit
from the extract removed the translation inhibition, and diminished the
gel shift, the addition of the C subunit to purified LPL mRNA
did not cause a gel shift. Thus, the C subunit by itself was not
sufficient to cause translation inhibition. This information, along
with the presence of other proteins in the 3'-UTR column elution,
suggests the presence of an RNA binding complex.
Because of this evidence for an RNA binding complex, we examined the
epinephrine-treated cell extract for other PKA-associated proteins.
Using both a ligand blot and specific antibodies, we identified
AKAP121/149 as another component of the RNA binding complex from
epinephrine-treated cells. Treatment of cells with Ht31 eliminated
epinephrine-mediated inhibition of LPL translation, indicating that the
linkage of PKA to AKAPs was critical to LPL physiologic regulation.
AKAPs include several families of PKA anchoring proteins, which
function to immobilize PKA at specific intracellular locations (13,
36). All AKAPs contain a PKA R subunit binding site, along with a
targeting domain that determines the subcellular location. AKAP149 and
AKAP121 are part of a family of AKAPs that are expressed in germ cells,
thyroid, heart, and skeletal muscles (26, 27, 37). The AKAPs 149 and
121 are highly homologous and both contain a consensus KH domain,
giving these proteins potential RNA binding properties. However, no
previous study has clearly linked AKAPs 149/121 to RNA binding, and no
previous study has described AKAP149/121 expression in adipose tissue.
AKAPs 149 and 121 are designated by their apparent molecular weight on
protein gels, even though their predicted molecular weight is lower
(13). Previous studies have suggested that AKAP149 is the human
homologue of AKAP121 (19). The experiments described in this report
involved 3T3-F442A adipocytes, which is a mouse cell line. Hence, one
would expect to find AKAP121 in these cells, rather than AKAP149.
Although we cannot be certain which member of the AKAP family has been
identified, the AKAP species migrates at ~121 kDa and interacts with
R subunit in the ligand blot and antibodies to AKAP121/149, and we have
referred to this protein as AKAP149/121.
Because the inactivation of C kinase activity with H89 prevented the
gel shift with the LPL mRNA, C subunit kinase activity was
important, perhaps through phosphorylation of AKAP121/149, which was
also phosphorylated. These data are most consistent with a complex role
for PKA C subunit in the regulation of LPL translation, where the
protein is part of a multimeric RNA binding complex involving
AKAP121/149, and perhaps other proteins which have not yet been
characterized, and whose RNA binding activity is dependent on PKA
kinase activity. As shown in Fig. 8, the
PKAs consist of a heterotetrameric holoenzyme containing two C subunits bound to a regulatory R subunit dimer (13, 38, 39). In the absence of
cAMP, the heterodimer is inactive, and upon binding of two molecules of
cAMP to each R subunit, the two C subunits are released to
phosphorylate serine and threonine residues on many different protein
substrates. There are numerous isozymes of PKA because of different R
and C subunits, and adipose tissue expresses mainly the RII , C ,
and C 1 subunits (40). AKAPs are important in directing PKA activity
to specific cellular sites, and likely play additional roles in
coordinating PKA tissue-specific functions. Our data suggest that
AKAP149/121 and PKA C are both involved in the LPL RNA binding
complex. However, co-precipitation experiments indicated that the C
subunit was not directly associated with AKAP. It is possible that
AKAP149/121 and the C subunit bind to different regions of the LPL RNA.
Alternatively, another protein may be involved in the RNA binding
complex. In addition, the relatively large amount C that was
detected on the colloidal blue-stained gel (Fig. 1) may suggest that
multiple copies of C subunit are involved in the complex. Finally, the
PKA regulatory subunit was not eluted from the LPL 3'-UTR column,
suggesting that the AKAP became separated from the PKA complex, or
perhaps was lost in the purification scheme.
Although no previous study has demonstrated PKA mediated RNA binding,
there are numerous instances of PKA mediated stimulation of RNA-binding
proteins. Previous studies have demonstrated cAMP-mediated activation
of RNA-binding proteins that control mRNA stability through binding
to the 3'-UTR of target RNAs, including Glut1, the
Na+/glucose cotransporter, lactate dehydrogenase, and
phosphoenolpyruvate carboxykinase (41-45). In many instances, the
cAMP-dependent RNA-binding protein binds to an AU-rich
region on the target mRNA, although there are no clear homologies
or consensus sequences among either the cis-acting RNA elements or the
trans-acting binding proteins.
In our experiments, some gel-shift product was also present in control
(no epinephrine treatment) cells. This suggests a constitutive expression of PKA C in the cells, and is consistent with previous studies by us and others. In a previous study, we found that adipocytes from hypothyroid rats demonstrated increased LPL translation because of
the absence of a constitutive LPL translation inhibitor (46). The
hypothyroid state is known to decrease catecholamine sensitivity (47),
which would be predicted to decrease cAMP stimulation of PKA. Thus, the
LPL RNA inhibitor in these previous studies was likely a low level of
constitutive PKA C , which was then decreased in the hypothyroid adipocytes.
In adipose tissue, hormones that cause elevated cAMP ( -adrenergic
agonists, ACTH, and glucagon) result in the activation of PKA, which
then reversibly phosphorylates HSL (2, 3), resulting in adipocyte
lipolysis and the release of nonesterified fatty acids from adipocytes.
Lipolysis is the physiologic reverse reaction to LPL-mediated
triglyceride accumulation, and therefore PKA C is an appropriate
candidate for an LPL-inhibitory signal. These data would suggest that
cAMP stimulation results in a coordinated response to rapidly promote
release of adipocyte lipid and inhibition of lipogenesis through
post-transcriptional mechanisms.
 |
ACKNOWLEDGEMENTS |
We are pleased to acknowledge Annadell
Fowler, Linda Bates, and Rami Kaakaji for technical assistance and
Sarah Dunn for secretarial assistance.
 |
FOOTNOTES |
*
This work was supported by a Career Development Award from
the American Diabetes Association (to G. R.), Grant DK 39176 from the National Institute of Health, and a Merit Review Grant from the
Veterans Administration.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Research, 151 LR,
Central Arkansas Veterans Healthcare System, 4300 W. 7th St., Little
Rock, AR 72205. Tel.: 501-257-4816; Fax: 501-257-4821; E-mail:
kernphilipa@uams.edu.
Published, JBC Papers in Press, September 5, 2002, DOI 10.1074/jbc.M202560200
 |
ABBREVIATIONS |
The abbreviations used are:
LPL, lipoprotein lipase;
PKA, protein kinase A;
HSL, hormone-sensitive
lipase;
UTR, untranslated region;
AKAP, A kinase anchoring
protein;
ACTH, adrenocorticotropic hormone.
 |
REFERENCES |
| 1.
|
Goldberg, I. J.
(1996)
J. Lipid Res.
37,
693-707[Abstract]
|
| 2.
|
Stralfors, P.,
Bjorgell, P.,
and Belfrage, P.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
3317-3321[Abstract/Free Full Text]
|
| 3.
|
Holm, C.,
Langin, D.,
Manganiello, V.,
Belfrage, P.,
and Degerman, E.
(1997)
Methods Enzymol.
286,
45-67[Medline]
[Order article via Infotrieve]
|
| 4.
|
Osuga, J.,
Ishibashi, S.,
Oka, T.,
Yagyu, H.,
Tozawa, R.,
Fujimoto, A.,
Shionoiri, F.,
Yahagi, N.,
Kraemer, F. B.,
Tsutsumi, O.,
and Yamada, N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
787-792[Abstract/Free Full Text]
|
| 5.
|
Kelley, D. E.,
and Simoneau, J. A.
(1994)
J. Clin. Invest.
94,
2349-2356[Medline]
[Order article via Infotrieve]
|
| 6.
|
Unger, R. H.
(1995)
Diabetes
44,
863-870[Abstract]
|
| 7.
|
Eckel, R. H.
(1987)
in
Lipoprotein Lipase
(Borensztajn, J., ed)
, pp. 79-132, Evener, Chicago
|
| 8.
|
Londos, C.,
Brasaemle, D. L.,
Schultz, C. J.,
Adler-Wailes, D. C.,
Levin, D. M.,
Kimmel, A. R.,
and Rondinone, C. M.
(1999)
Ann. N. Y. Acad. Sci.
892,
155-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Ramsay, T. G.
(1996)
Endocrinol. Metab. Clin. North Am.
25,
847-870[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Ong, J. M.,
Saffari, B.,
Simsolo, R. B.,
and Kern, P. A.
(1992)
Mol. Endocrinol.
6,
61-69[Abstract/Free Full Text]
|
| 11.
|
Yukht, A.,
Davis, R. C.,
Ong, J. M.,
Ranganathan, G.,
and Kern, P. A.
(1995)
J. Clin. Invest.
96,
2438-2444[Medline]
[Order article via Infotrieve]
|
| 12.
|
Ranganathan, G., Vu, D.,
and Kern, P. A.
(1997)
J. Biol. Chem.
272,
2515-2519[Abstract/Free Full Text]
|
| 13.
|
Feliciello, A.,
Gottesman, M. E.,
and Avvedimento, E. V.
(2001)
J. Mol. Biol.
308,
99-114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Wion, K. L.,
Kirchgessner, T. G.,
Lusis, A. J.,
Schotz, M. C.,
and Lawn, R. M.
(1987)
Science
235,
1638-1641[Abstract/Free Full Text]
|
| 15.
|
Chijiwa, T.,
Mishima, A.,
Hagiwara, M.,
Sano, M.,
Hayashi, K.,
Inoue, T.,
Naito, K.,
Toshioka, T.,
and Hidaka, S.
(1990)
J. Biol. Chem.
265,
5267-5272[Abstract/Free Full Text]
|
| 16.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 17.
|
Furusawa, M.,
Ohnishi, T.,
Taira, T.,
Iguchi-Ariga, S. M.,
and Ariga, H.
(2001)
J. Biol. Chem.
276,
36647-36651[Abstract/Free Full Text]
|
| 18.
|
Tso, J. Y.,
Sun, X. H.,
Kao, T. H.,
Reece, K. S.,
and Wu, R.
(1985)
Nucleic Acids Res.
13,
2485-2502[Abstract/Free Full Text]
|
| 19.
|
Chen, Q.,
Lin, R. Y.,
and Rubin, C. S.
(1997)
J. Biol. Chem.
272,
15247-15257[Abstract/Free Full Text]
|
| 20.
|
Ranganathan, G.,
Kaakaji, R.,
and Kern, P. A.
(1999)
J. Biol. Chem.
274,
9122-9127[Abstract/Free Full Text]
|
| 21.
|
Hausken, Z. E.,
Coghlan, V. M.,
and Scott, J. D.
(1997)
in
Protein Targeting Protocols
(Clegg, R. A., ed)
, pp. 47-64, Humana Press, Totowa, NJ
|
| 22.
|
Xie, G.,
and Raufman, J. P.
(2001)
Am. J. Physiol.
281,
G1051-G1058[Abstract/Free Full Text]
|
| 23.
|
Ong, J. M.,
Kirchgessner, T. G.,
Schotz, M. C.,
and Kern, P. A.
(1988)
J. Biol. Chem.
263,
12933-12938[Abstract/Free Full Text]
|
| 24.
|
Goers, J. F.,
Petersen, M. E.,
Kern, P. A.,
Ong, J.,
and Schotz, M. C.
(1987)
Anal. Biochem.
166,
27-35[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Carr, D. W.,
Hausken, Z. E.,
Fraser, I. D.,
Stofko-Hahn, R. E.,
and Scott, J. D.
(1992)
J. Biol. Chem.
267,
13376-13382[Abstract/Free Full Text]
|
| 26.
|
Lin, R. Y.,
Moss, S. B.,
and Rubin, C. S.
(1995)
J. Biol. Chem.
270,
27804-27811[Abstract/Free Full Text]
|
| 27.
|
Trendelenburg, G.,
Hummel, M.,
Riecken, E. O.,
and Hanski, C.
(1996)
Biochem. Biophys. Res. Commun.
225,
313-319[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Ashley, C. T. J.,
Wilkinson, K. D.,
Reines, D.,
and Warren, S. T.
(1996)
Science
262,
563-566
|
| 29.
|
Ong, J. M.,
Simsolo, R. B.,
Saffari, B.,
and Kern, P. A.
(1992)
Endocrinology
130,
2310-2316[Abstract/Free Full Text]
|
| 30.
|
Ong, J. M.,
and Kern, P. A.
(1989)
J. Clin. Invest.
84,
305-311[Medline]
[Order article via Infotrieve]
|
| 31.
|
Doolittle, M. H.,
Ben-Zeev, O.,
Elovson, J.,
Martin, D.,
and Kirchgessner, T. G.
(1990)
J. Biol. Chem.
265,
4570-4577[Abstract/Free Full Text]
|
| 32.
|
Ong, J. M.,
and Kern, P. A.
(1989)
J. Biol. Chem.
264,
3177-3182[Abstract/Free Full Text]
|
| 33.
|
Simsolo, R. B.,
Ong, J. M.,
Saffari, B.,
and Kern, P. A.
(1992)
J. Lipid Res.
33,
89-95[Abstract]
|
| 34.
|
Tavangar, K.,
Murata, Y.,
Pedersen, M. E.,
Goers, J. F.,
Hoffman, A. R.,
and Kraemer, F. B.
(1992)
J. Clin. Invest.
90,
1672-1678[Medline]
[Order article via Infotrieve]
|
| 35.
|
Ranganathan, G., Li, C.,
and Kern, P. A.
(2000)
J. Biol. Chem.
275,
40986-40991[Abstract/Free Full Text]
|
| 36.
|
Diviani, D.,
and Scott, J. D.
(2001)
J. Cell Sci.
114,
1431-1437[Abstract]
|
| 37.
|
Feliciello, A.,
Rubin, C. S.,
Avvedimento, E. V.,
and Gottesman, M. E.
(1998)
J. Biol. Chem.
273,
23361-23366[Abstract/Free Full Text]
|
| 38.
|
Walsh, D. A.,
Perkins, J. P.,
and Krebs, E. G.
(1968)
J. Biol. Chem.
243,
3763-3765[Abstract/Free Full Text]
|
| 39.
|
Francis, S. H.,
and Corbin, J. D.
(1999)
Crit. Rev. Clin. Lab. Sci.
36,
275-328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
McKnight, G. S.,
Cummings, D. E.,
Amieux, P. S.,
Sikorski, M. A.,
Brandon, E. P.,
Planas, J. V.,
Motamed, K.,
and Idzerda, R. L.
(1998)
Recent Prog. Horm. Res.
53,
139-159[Medline]
[Order article via Infotrieve]
|
| 41.
|
Tian, D.,
Huang, D.,
Brown, R. C.,
and Jungmann, R. A.
(1998)
J. Biol. Chem.
273,
28454-28460[Abstract/Free Full Text]
|
| 42.
|
Stephens, J. M.,
Carter, B. Z.,
Pekala, P. H.,
and Malter, J. S.
(1992)
J. Biol. Chem.
267,
8336-8341[Abstract/Free Full Text]
|
| 43.
|
Hod, Y.,
and Hanson, R. W.
(1988)
J. Biol. Chem.
263,
7747-7752[Abstract/Free Full Text]
|
| 44.
|
Christ, B.,
Heise, T.,
and Jungermann, K.
(1991)
Biochem. Biophys. Res. Commun.
177,
1273-1282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Peng, H.,
and Lever, J. E.
(1995)
J. Biol. Chem.
270,
23996-24003[Abstract/Free Full Text]
|
| 46.
|
Kern, P. A.,
Ranganathan, G.,
Yukht, A.,
Ong, J. M.,
and Davis, R.
(1996)
J. Lipid Res.
37,
2332-2340[Abstract]
|
| 47.
|
Bilezikian, J. P.,
and Loeb, J. N.
(1983)
Endocr. Rev.
4,
378-396[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. J. Horton, S. Dow, M. Armstrong, and W. T. Donahoo
Greater systemic lipolysis in women compared with men during moderate-dose infusion of epinephrine and/or norepinephrine
J Appl Physiol,
July 1, 2009;
107(1):
200 - 210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rogne, A. J. Stokka, K. Tasken, P. Collas, and T. Kuntziger
Mutually exclusive binding of PP1 and RNA to AKAP149 affects the mitochondrial network
Hum. Mol. Genet.,
March 1, 2009;
18(5):
978 - 987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Banga, R. Unal, P. Tripathi, I. Pokrovskaya, R. J. Owens, P. A. Kern, and G. Ranganathan
Adiponectin translation is increased by the PPAR{gamma} agonists pioglitazone and {omega}-3 fatty acids
Am J Physiol Endocrinol Metab,
March 1, 2009;
296(3):
E480 - E489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ma and S. S. Taylor
A Molecular Switch for Targeting between Endoplasmic Reticulum (ER) and Mitochondria: CONVERSION OF A MITOCHONDRIA-TARGETING ELEMENT INTO AN ER-TARGETING SIGNAL IN DAKAP1
J. Biol. Chem.,
April 25, 2008;
283(17):
11743 - 11751.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Liu, W. Ding, J. Neiman, and K. M. Mulder
Requirement of Smad3 and CREB-1 in Mediating Transforming Growth Factor-beta (TGFbeta) Induction of TGFbeta3 Secretion
J. Biol. Chem.,
October 6, 2006;
281(40):
29479 - 29490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhang, A. Lookene, G. Wu, and G. Olivecrona
Calcium Triggers Folding of Lipoprotein Lipase into Active Dimers
J. Biol. Chem.,
December 30, 2005;
280(52):
42580 - 42591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ricart-Jane, P. Cejudo-Martin, J. Peinado-Onsurbe, M. D. Lopez-Tejero, and M. Llobera
Changes in lipoprotein lipase modulate tissue energy supply during stress
J Appl Physiol,
October 1, 2005;
99(4):
1343 - 1351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Jungmann and O. Kiryukhina
Cyclic AMP and AKAP-mediated Targeting of Protein Kinase A Regulates Lactate Dehydrogenase Subunit A mRNA Stability
J. Biol. Chem.,
July 1, 2005;
280(26):
25170 - 25177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wu, P. Brouckaert, and T. Olivecrona
Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: evidence that TNF-{alpha} is involved
Am J Physiol Endocrinol Metab,
May 1, 2004;
286(5):
E711 - E717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Salzmann, M. Otis, H. Long, C. Roberge, N. Gallo-Payet, and C.-D. Walker
Inhibition of Steroidogenic Response to Adrenocorticotropin by Leptin: Implications for the Adrenal Response to Maternal Separation in Neonatal Rats
Endocrinology,
April 1, 2004;
145(4):
1810 - 1822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sowa, H. Kaji, M. F. Iu, T. Tsukamoto, T. Sugimoto, and K. Chihara
Parathyroid Hormone-Smad3 Axis Exerts Anti-apoptotic Action and Augments Anabolic Action of Transforming Growth Factor {beta} in Osteoblasts
J. Biol. Chem.,
December 26, 2003;
278(52):
52240 - 52252.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|